Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites

News

2004-10-08:
International Prix Galien 2004: Revolutionary HIV Drug Fuzeon Receives Most Prestigious Award for Innovation in Pharmaceutical Industry
Basel, Switzerland ( PRN/ots ) - Today, HIV drug Fuzeon ( enfuvirtide or T - 20 ) was awarded the 2004 International Prix Galien for the most innovative new medicine. Fuzeon was selected out of 12 major new drugs in all therapeutic areas which each won national awards. Since (...)
2008-09-18:
Enbrel( R ) Shown to Deliver Long - Lasting Improvements in Psoriasis Patients' Quality of Life
Maidenhead, England ( PRN/ots ) - - New Study Results Further Support That Enbrel Effectively Clears Skin, Reduces the Prevalence of Depression and Anxiety and Improves Patients' Quality of Life Data demonstrating the significant positive impact of Enbrel ( etanercept ) on the quality of life of (...)
2010-03-17:
Agendia to Play Pivotal Role in ISPY - 2 Trial for Breast Cancer
HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I - SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research (...)
2006-08-02:
Medify Solutions Limited ( Pink Sheets MFYS ) Explains the Sales Potential for UK Remote Access Market
Gateshead, England ( PRN/ots ) - On the 1st September 2006, Medify Solutions Limited will roll out its 'remote access to patient notes' product, MedifyRemote, to its National Health Service ( NHS ) customers. The first NHS site, as published previously , will be in Doncaster in the (...)
2009-10-05:
Study Finds That ONGLYZA( TM ) ( saxagliptin ) When Added to Metformin was Non - Inferior to JANUVIA ( sitagliptin ) When Added to Metformin in Reducing Hemoglobin ( HbA1c ) in Adults With Type 2 Diabetes Mellitus
Princeton, New Jersey and London ( PRN/ots ) - Results from an 18 - week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA( TM ) ( saxagliptin ) 5 mg per day achieved (...)
2009-03-19:
Occlutech obtains favourable ruling in proceedings initiated by AGA Medical
Jena ( na Originaltextservice ) - Occlutech GmbH today announced that it had defeated a request for insolvency, launched at the Amtsgericht Gera in Germany by its US competitor AGA Medical. The request by AGA was based on wrongful assumptions about Occlutech, and AGA announced (...)
2006-07-13:
Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces
Toronto ( PRN/ots ) - Medify Solutions Limited today announces its own in - house product for roll out to the NHS. This new capability will replace the legacy generic solution provided for Medify by Pervasic and specifically focuses on the known requirements of Healthcare professionals (...)
2005-11-18:
New Study Shows Patients More Willing to Consider Self - Injectable HIV Therapy Than Many Physicians Anticipate
Dublin, Ireland, November 18 ( PRN/ots ) - - Latest Advances in Health Psychology may Help Physicians Implement Improved HIV Care - News From 10th European AIDS Conference, Dublin, Ireland Initial results from the OpenMind study, the largest behavioural study to look at both patients' (...)
2006-04-21:
Boston Scientific Completes Combination With Guidant
Natick, Massachusetts ( PRN/ots ) - Boston Scientific Corporation ( NYSE: BSX ) today announced that it has completed its combination with Guidant Corporation ( NYSE: GDT ), creating a global leader in cardiovascular devices and one of the largest medical technology companies in the world. In a related transaction (...)
2008-03-05:
New 300mg Loading Dose Tablet for Plavix( R ) Receives Positive Opinion From the European Committee for Medicinal Products ( CHMP )
Paris and Princeton, New Jersey ( PRN/ots ) - - A New Step Forward May Help Increase Appropriate Early Use of Plavix( R ) by Simplifying Administration in Acute Coronary Syndrome Patients Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) and Bristol - Myers Squibb Company ( NYSE: BMY ) announced (...)
2005-05-25:
Siemens Medical Solutions Standardizes On Astoria Software, Common Platform Speeds Delivery of Tech Data, Improves Ease of Use
Amsterdam, Netherlands ( PRN/ots ) - - XML Content Management System at Heart of New User - Centric Solution That Brings Consistency to Technical Documents Across 100s of Medical Products Astoria Software, the leading provider of XML content management solutions, today announced that Siemens Medical Solutions (...)
2007-09-19:
New Data Confirm Clear Benefit of Protelos( R ) ( Strontium Ranelate ) in the Treatment of Postmenopausal Osteoporosis
Honolulu, Hawaii ( PRN/ots ) - - Protelos( R ) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos( R ) ( strontium ranelate ) stimulates bone formation and increases bone volume by 30 Prozent in high fracture risk patients who have been on long term (...)
2006-05-17:
Continental Global Engineering Excellence Initiative
Boston/Hanover ( na Originaltextservice ) - Study on the Future of Engineering Takes Shape Eight top international universities compile initial findings of their research on engineering science - Internationalization of universities a key to success Universities with highly demanding engineering programs must intensify (...)
2007-10-10:
New Survey Conveys Fundamental Shift in the Perceptions of Treatment Outcomes in Schizophrenia
Leuven, Belgium ( PRN/ots ) - - EUFAMI Survey Shows Carers Across Europe Believe in Remission as a Realistic Treatment Goal for Many People Living With Schizophrenia A large majority of families who care for someone with schizophrenia are confident that many people with (...)
2009-12-17:
Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany ( PRN/ots ) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late - stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME - Ovar - 1 (...)
2006-09-11:
Degussa Presents European Science - to - Business Award / New nano - process for magnetic storage - 100,000 euros for Prof. Russell Cowburn
Dusseldorf, Germany ( na Originaltextservice ) - - Cross - reference: photo ( Russell Cowburn, professor of nanotechnology ) is available at http://www.presseportal.de/galerie.html Russell Cowburn, 36, Professor of Nanotechnology at the renowned Imperial College, London, is the winner of the "Degussa European Science - (...)
2010-01-06:
New Abbott Gene - Based Test for Colorectal Cancer Receives CE Mark
Des Plaines, Illinois ( PRN/ots ) - Abbott announced today it has received CE Marking ( Conformite Europeene ) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non - invasive DNA assay that detects the methylated form of Septin 9, a (...)
2008-05-06:
Making a Real Difference to the Lives of Asthma Patients
Southampton, England ( PRN/ots ) - - Leading Asthma Expert Calls for Action On the occasion of World Asthma Day on 6 May, leading asthma expert Professor Stephen Holgate from the University of Southampton ( UK ) says: "I am delighted that the theme of this (...)
2007-12-17:
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
San Antonio, Texas ( PRN/ots ) - - Roche in Collaboration With Genentech Commit to Large Phase III Adjuvant Clinical Programme Set to Unlock Avastin's Potential in Early Breast Cancer According to new phase II study data, Avastin ( bevacizumab ) can proceed to be tested after (...)
2008-10-31:
Largest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem
Ingelheim, Germany ( PRN/ots ) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under - Recognised and Under - Diagnosed - For non - US media only Results from the PRESIDE*( 1 ) survey, (...)
2011-02-04:
First Study Estimates Economic Impact of Dengue Illness in Americas at $2.1 Billion Per Year
Deerfield, Illinios ( PRN/ots ) - The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus ( HPV ) and rotavirus. Results of the study (...)
2011-01-19:
International Society for Cellular Therapy ( ISCT ) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease
Vancouver ( PRN/ots ) - In keeping with its commitment to connect industry, regulatory experts, therapeutic societies and translational centers to advance emerging cellular therapies, ISCT announces its first commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease ( PVD ). PVD is a condition in which (...)
2010-06-15:
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti - VEGF PRS - 050 is first Anticalin tested in humans
Freising - Weihenstephan ( na Originaltextservice ) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS - 050, an anti - VEGF Anticalin. The trial is an open - label, dose - escalating evaluation of the compound's (...)
2006-08-14:
Tipranavir Achieves Virologic and Immunologic Improvements in HIV - Positive Children at 48 - Weeks of Therapy
Toronto ( PRN/ots ) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV - 1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference ( IAC ) in Toronto, Canada. Results from (...)
2006-12-14:
Landmark Study of Avastin in Lung Cancer Published Today in New England Journal of Medicine
Basel, Switzerland ( PRN/ots ) - - Avastin is First Medicine to Extend Survival Beyond One Year in Patients With Previously Untreated Non - Small Cell Lung Cancer Avastin is the first medicine proven to help previously untreated patients suffering from the most common form (...)
2006-06-19:
Anticipated Approval of Latest HIV Drug Will Give Treatment - Experienced Patients the Best Chance Yet to Achieve Undetectable Viral Load
Basel, Switzerland ( PRN/ots ) - - Newest HIV Drug Works Better in Combination With FUZEON( R ) The emergence of new HIV treatments, such as boosted protease inhibitors ( PI ), has led to a change in treatment goals for people living with drug - resistant HIV. Up (...)
2007-12-05:
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
Copenhagen ( PRN/ots ) - - Attention Medical Trade Press Only - Further Study Demonstrates Efficacy and Tolerability of Escitalopram in Premenstrual Dysphoric Disorder New data released today reinforces the superiority of escitalopram compared to duloxetine in the acute treatment of depression and provides a further (...)
2006-11-02:
EMIS Prepares for MedifyRemote Roll Out
Toronto, Canada, November 2 ( PRN/ots ) - EMIS, the UK's leading provider of IT systems to the primary care market is preparing to make the MedifyRemote product available across its UK customer base. Approximately 55 Prozent of all doctors in the UK currently use EMIS software (...)
2008-02-14:
Major International Diabetes Study Does not Confirm Increased Risk of Death Reported by US Trial
Paris ( PRN/ots ) - - Preliminary Findings from the Largest - Ever Study of Treatments for Diabetes Provide no Evidence That Intensive Treatment to Lower Blood Glucose ( Sugar ) Increases Risk of Death Interim results from the ADVANCE Study, involving 11,140 high - risk patients with type (...)
2004-12-02:
Isotechnika Initiates Canadian Phase III Psoriasis Trial
Edmonton, Alberta ( PRN/ots ) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing (...)
2010-03-15:
New ANTEK MultiTek[TM] Introduced - Provides Fast, All - in - One Testing for Sulfur, Nitrogen, Halides
Houston, Texas, USA ( na Originaltextservice ) - PAC officially announces the introduction of the ANTEK MultiTek[TM] testing system for the fast, accurate detection of sulfur, nitrogen, and halides. "MultiTek[TM] is the only instrument on the market that combines testing for sulfur, nitrogen, (...)
2009-05-12:
Occlutech obtains CE mark for the new generation PFO & ASD occluders
Jena ( na Originaltextservice ) - Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex. The Figulla Flex ASD and PFO occluders encompass a new (...)
2008-07-09:
Industry Leaders Select Resverlogix's RVX - 208 Among Top 10 Most Promising Drugs
Calgary, Canada ( PRN/ots ) - Resverlogix Corp's ( "Resverlogix" or the "Company" ) ( TSX:RVX ) novel lead ApoA - I drug candidate, RVX - 208 has been selected as one of the top 10 most promising cardiovascular disease ( CVD ) drugs available for strategic partnering by an independent committee assembled (...)
2009-11-30:
Sanofi - aventis: Multaq( R ) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 ( PRN/ots ) - - First New Anti - Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the European Commission has granted marketing authorization for Multaq( R ) ( dronedarone - (...)
2005-11-14:
Fournier Pharma Announces Results of the Largest Clinical Trial in Patients With Type 2 Diabetes Demonstrating Positive Effects of Fenofibrate Therapy on Cardiovascular Events
Dallas, Texas, November 14 ( PRN/ots ) - - FIELD Confirms Fenofibrate Produces Macrovascular and Microvascular Benefits in Diabetic Patients Without Previous Cardiovascular Disease Although Primary Endpoint is not met Results of the largest intervention study ever conducted for the prevention of cardiovascular disease in (...)
2010-03-09:
Kimble Chase announces the availability of a new line of laboratory glassware
New Jersey, USA ( na Originaltextservice ) - Kimble Chase, a leader in the scientific laboratory glassware industry, is pleased to announce the introduction of its ValueWare® line of products. ValueWare® is designed from ISO and ASTM standards and is characterized by a unique combination (...)
2010-07-08:
Unprecedented Donation Made by Mrs. Lily Safra to the Institute for Brain and Spinal Cord Disorders in Paris
Paris, July 8, 2010 ( PRN/ots ) - Professor Gerard Saillant, President of the Institute for Brain and Spinal Cord Disorders ( ICM ), announced today an unprecedented donation of EUR8,000,000 from Mrs. Lily Safra. It is the largest single donation made by a private individual to the (...)
2010-08-17:
Kowa Announces First EU Marketing Authorisation for Pitavastatin Granted in the UK
Wokingham, England, August 17, 2010 ( PRN/ots ) - Kowa are delighted to announce that the Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a UK licence for their statin, Livazo( R ) ( pitavastatin ). This follows the completion of the decentralized regulatory procedure, in which the MHRA (...)
2010-06-30:
Mars hosts key scientific panel discussion at one of the largest ever gatherings of Nobel Laureates
Lindau, Germany ( na Originaltextservice ) - - Bildmaterial ist abrufbar unter http://www.presseportal.de/galerie.htx?type=obs - To tackle the world's most pressing issues, genuine collaboration between the academic community, government and industry is needed, Mars, Incorporated said yesterday. As part of (...)
2010-04-15:
Growing Threat From Potentially Lethal Diseases Highlighted at Meeting of Global Experts
New York, April 15, 2010 ( PRN/ots ) - As experts from around the world met in New York this week they discussed the need for greater understanding of the threat posed by ticks, fleas and sand flies. Leading scientists called on veterinarians and dog - (...)
2008-09-15:
Pan - European Research Reveals Majority of Osteoporosis Patients not Receiving Recommended Combination of Calcium and Vitamin D With Treatment
Geneva ( PRN/ots ) - - Study Highlights Underlying Reasons for why Patients are Missing Their Supplementation GENEVA, September 15 /PRNewswire/ - - New research published today at the annual meeting of the American Society for Bone and Mineral Research ( ASBMR ), Montréal, Canada, reveals that less than (...)
2006-06-29:
GE Healthcare Collaborates With Manipal Health Systems to Conduct Clinical Studies of Medical Diagnostic Products in India
Bangalore, India ( PRN/ots ) - - Company's First Integrated Development Center ( IDC ) Opens in Bangalore as Part of Strategic Development of its Global Clinical Studies Program GE Healthcare, a division of the General Electric Company ( NYSE:GE ) today announced the opening of its first (...)
2010-04-06:
Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban
Tokyo, April 6, 2010 ( PRN/ots ) - Daiichi Sankyo Company, Limited announced today that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan seeking approval of the anticoagulant, edoxaban, for the prevention of venous thromboembolism ( VTE ) after (...)
2006-10-26:
Short and Long - Term Efficacy of Spinal Stabilisation System Investigated in Patients With Lower Back Pain
Tolochenaz, Switzerland ( PRN/ots ) - A new study announced today by Medtronic will investigate the short and long - term benefits of adding a spinal stabilisation system to a standard herniectomy procedure in patients with spinal disc herniation. The study is the first randomised control trial (...)
2009-09-22:
Denosumab Demonstrates Superiority Over Zometa( R ) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from a Phase 3, head - to - head trial evaluating denosumab versus Zometa( R ) ( zoledronic acid ) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its (...)
2011-03-04:
ONGLYZA( R ) Becomes the First DPP - 4 Inhibitor Available for Use in Europe
Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( http://www.bms.com ) and AstraZeneca ( http://www.astrazeneca.com ) today announced that the European Commission has approved a label update for ONGLYZA( R ) ( saxagliptin ) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. (...)
2005-06-09:
Interpharma, Quintiles and Temasek to Form Pharma Commercialization Joint Venture in Asia Pacific With US$112 Million Investment Fund
Hong Kong and Singapore and Research Triangle Park, North Carolina ( PRN/ots ) - Three global companies have announced a joint venture to commercialize pharmaceutical products in the Asia Pacific region. Partners in the joint venture, which will have an investment fund totaling US$112 million, include (...)
2004-10-30:
Femara( r ) Gains U.S. FDA Approval as Only Post - Tamoxifen Treatment for Early Breast Cancer
Basel, Switzerland ( PRN/ots ) - - New Treatment Option the First to Help Postmenopausal Women With Early Breast Cancer Remain Cancer - Free Following Adjuvant Tamoxifen Therapy Femara( R ) ( letrozole ) is the first therapy approved by the U.S. Food and Drug Administration ( FDA ) for the extended (...)
2010-11-24:
HOYA Discusses the Future of Progressive Lenses on a Global Level
Uithoorn, Netherlands, November 24 ( PRN/ots ) - From 27 September until 1 October HOYA Vision Care invited a selection of its best lens experts and VIP customers from all over the world to join its Global PAL Summit in La Toja, Spain. Goal was (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...



» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
Biotechnology
International
Databases
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Acne
Cancer
Diabetes
Nutrition and Diet
Family
Fitness and Sports
Forums
Womens Health
Genetics
Health-Marketing
Dating
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Organizations
Care
Portals and Directories
Pharmacies
Portals and Directories Dental Medicine
Search
Psyche
Public Health
Governmental Links
Guides
Regional
Baden-Wuerttemberg
Bavaria
Berlin
North Rhine-Westphalia
Travel Medicine
Self-Help
AIDS
Alcoholism
Alzheimer
Medical malpractice
Visually Impaired
Seminar
Seniors / 50+
Seniors / Living
Shopping
Medical Technology
Children-, Youth- and Social Work
Scholastics
Accommodation
Organization
Mixed


© 2003-2008 med-kolleg.de Health Provider Directory
Clinics and Physicians
Berlin, Germany Dienstag, 22.10.2019.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Sun, 20 Oct 2019 10:24:13 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche
Gesundheitsportal